Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-62

What I like most about this announcement is that it shows the strength of IMU technical (medical) team. They obviously saw the potential of Azer-Cel and had the confidence to know they could run the trials at a faster rate then the previous owners of the technology.
This announcement is as much about the quality of our team as much as the quality of our technology. That includes a BOD that are willing to back their team and make a major purchase when market sentiment was against them and SPP was at a 2 year low....Balls.
This is the advantage that small caps have over BP and Imugene are using it beautifully. This is the corporate equivalent of Julius Caesar crossing the Rubicon I am excited to be a part of it.